Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia.
Authors
Huntly, B JReid, A G
Bench, A J
Campbell, L J
Telford, Nicholas
Shepherd, P
Szer, J
Prince, H M
Turner, P
Grace, C
Nacheva, E P
Green, Anthony R
Affiliation
Department of Hematology, University of Cambridge, Cambridge, United Kingdom.Issue Date
2001-09-15
Metadata
Show full item recordAbstract
Chronic myeloid leukemia (CML) is characterized by formation of the BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22. Large deletions on the derivative chromosome 9 have recently been reported, but it was unclear whether deletions arose during disease progression or at the time of the Ph translocation. Fluorescence in situ hybridization (FISH) analysis was used to assess the deletion status of 253 patients with CML. The strength of deletion status as a prognostic indicator was then compared to the Sokal and Hasford scoring systems. The frequency of deletions was similar at diagnosis and after disease progression but was significantly increased in patients with variant Ph translocations. In patients with a deletion, all Ph(+) metaphases carried the deletion. The median survival of patients with and without deletions was 38 months and 88 months, respectively (P =.0001). By contrast the survival difference between Sokal or Hasford high-risk and non-high-risk patients was of only borderline significance (P =.057 and P =.034). The results indicate that deletions occur at the time of the Ph translocation. An apparently simple reciprocal translocation may therefore result in considerable genetic heterogeneity ab initio, a concept that is likely to apply to other malignancies associated with translocations. Deletion status is also a powerful and independent prognostic factor for patients with CML. The prognostic significance of deletion status should now be studied prospectively and, if confirmed, should be incorporated into management decisions and the analysis of clinical trials.Citation
Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. 2001, 98 (6):1732-8 BloodJournal
BloodPubMed ID
11535505Type
ArticleLanguage
enISSN
0006-4971Collections
Related articles
- Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.
- Authors: Huntly BJ, Bench A, Green AR
- Issue date: 2003 Aug 15
- Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.
- Authors: Huntly BJ, Bench AJ, Delabesse E, Reid AG, Li J, Scott MA, Campbell L, Byrne J, Pinto E, Brizard A, Niedermeiser D, Nacheva EP, Guilhot F, Deininger M, Green AR
- Issue date: 2002 Jun 15
- [Study of deletion of derivative chromosome 9 in patients with Ph+ chronic myeloid leukemia].
- Authors: Wu W, Xue YQ, Wu YF, Pan JL, Shen J
- Issue date: 2006 Mar
- Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia.
- Authors: Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntly B, Green AR
- Issue date: 2000 Feb 1
- A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
- Authors: Lee DS, Lee YS, Yun YS, Kim YR, Jeong SS, Lee YK, She CJ, Yoon SS, Shin HR, Kim Y, Cho HI
- Issue date: 2003 Jul